On June 22, Novo Nordisk rose 3.3% in regular trading, trading at $45.005/share, with turnover of $110 million. The stock gained momentum as the company's global CEO Mike Doustdar released a series of positive developments during his first visit to China.

On the news front, Doustdar announced plans to submit oral Wegovy clinical data to Chinese regulators within months seeking marketing approval, while committing an additional 200 million RMB investment to expand injection pen assembly capacity at the company's Tianjin facility. He also disclosed that Novo Nordisk will increase business development transactions in China, maintaining active dialogue with multiple Chinese companies. Notably, Eli Lilly submitted a marketing application in China for its oral obesity drug late last year, putting competitive pressure on Novo to accelerate its Chinese market entry.

Internationally, oral Wegovy recently received approval from the UK medicines regulator, becoming the first approved market in Europe, with clinical data demonstrating 13.6% average weight loss over 64 weeks. While semaglutide's patent expired in China in March, Novo retains regulatory data protection through early next year, providing a buffer against generic competition expected from Q2 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)